A Study of R-ICE and Lenalidomide for Treating Patients with First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma


About this study

The purpose of this study is to assess the side effects and best dose of lenalidomide when given together with rituximab-ifosfamide-carboplatin-etoposide (R-ICE) and how well they work in treating patients with diffuse large B-cell lymphoma that has returned after a period of improvement and that has not responded to previous treatment. Biological therapies, such as lenalidomide, may stimulate or suppress the immune system in different ways and stop cancer cells from growing. Drugs used in chemotherapy, such as R-ICE, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving lenalidomide with R-ICE may be a better treatment for patients with diffuse large B-cell lymphoma.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria

  • Phase I: Histological confirmation of expressing CD20 antigen as determined by pathology at the respective institution and central pathology review at Mayo Clinic Rochester. All types of B-cell lymphomas are allowed to participate. Patients with primary mediastinal large B-cell (PMLBCL) or transformed lymphoma are allowed to participate                                                                 
  • Phase II: Histological confirmation of  DLBCL expressing CD20 antigen as determined by pathology at the respective institution and central pathology review at Mayo Clinic Rochester.  Only Diffuse large B cell lymphoma patients are allowed to participate in Phase II. Patients with primary mediastinal large B-cell (PMLBCL) lymphoma or transformed lymphoma are not allowed to participate
  • Notes regarding slide submission
    • Central pathology review is mandatory but is retrospective in nature
    • Slides should be submitted within 30 days of enrollment
    • Patients can be enrolled prior to submission of slides
  • Has measurable disease (at least 1 lesion ≥ 1.5 cm in diameter) as detected by PET/CT
  • Only 1 line of previous anti-lymphoma therapy is allowed and not currently receiving any other agent that would be considered as a treatment for the lymphoma
  • Patients must be ≥ 2 weeks from prior anti-lymphoma therapy
  • The use of steroids and/or rituximab up to 1 week prior to registration for management of symptoms is allowed
  • Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-2
  • Absolute neutrophil count (ANC) ≥ 1500/mm^3
  • Platelet count ≥ 75,000/mm^3
  • Total bilirubin ≤ 2 × upper limit of normal (ULN) (unless related to lymphoma or Gilbert's disease) 
    • ≤ 5 × ULN for subjects with documented or suspected Gilbert's disease, or related to involvement of the liver by the lymphoma
  • Aspartate transaminase (AST) and alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) ≤ 3 x ULN unless evidence of the direct liver and/or bone involvement by lymphoma, then ≤ 5 x ULN
  • Phase I subjects must have calculated creatinine clearance ≥ 60 ml/min by Cockcroft-Gault formula
  • Phase II subjects must have calculated creatinine clearance ≥ 30 ml/min by Cockcroft-Gault formula
  • Negative pregnancy test done ≤10-14 days before registrationdays prior to registration, for women of childbearing potential only
  • Provide informed written consent
  • Willing to return to enrolling institution for follow-up during the active monitoring phase of the study, i.e. active treatment and observation
  • Willing to provide blood samples for correlative research purposes
  • Considered transplant-eligible, as determined by the opinion of the investigator at the participating institution
    • The participating institution does not need to be a transplant center but patients can be referred to a transplant center if needed
  • Willing and able to register into and comply with the mandatory requirements of Celgene's REVLIMID (lenalidomide) Risk Evaluation and Mitigation Strategies (REMS™) program
  • Females of reproductive potential are willing and able to adhere to the scheduled pregnancy testing as required by Celgene's REVLIMID REMS™ program
  • Willing and able to take aspirin (81 mg) daily as prophylactic anticoagulation
    • Patients intolerant to acetylsalicylic acid [ASA] may use warfarin or low molecular weight heparin

Exclusion Criteria

  • Pregnant women
  • Nursing women
  • Men or women of childbearing potential who are unwilling to employ adequate contraception
    • Men must agree to use a latex condom during sexual contact with a female of child-bearing potential even if they have had a successful vasectomy
    • Women of child bearing potential must agree to use 2 methods of reliable contraception simultaneously
    • All patients must be counseled at a minimum of every 21 days about pregnancy precautions and risks of fetal exposure
  • Has any co-morbid systemic illnesses or other severe concurrent disease which, in the judgment of the investigator, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens including, but not limited to
    • Ongoing or active infection
    • Symptomatic congestive heart failur
    • Unstable angina pectoris
    • Cardiac arrhythmia
    • Psychiatric illness/social situations that would limit compliance with study requirements
  • Immunocompromised patients and patients known to be human immunodeficiency virus (HIV) positive and currently receiving antiretroviral therapy
    • Patients known to be HIV positive, but without clinical evidence of an immunocompromised state, are eligible for this trial
    • Patients with HIV on antiretroviral therapy other than zidovudine (AZT) and/or stavudine and without prior acquired immunodeficiency syndrome (AIDS) defining conditions and adequate CD4 count > 400 are eligible
  • History of myocardial infarction ≤ 180 days prior to registration
  • Congestive heart failure requiring use of ongoing maintenance therapy for life-threatening ventricular arrhythmias
  • Receiving any other investigational agent which would be considered as a treatment for the primary neoplasm
    • Patients must be ≥ 2 weeks from prior anti-lymphoma therapy
    • The use of steroids and/or rituximab up to 1 week prior to registration for management of symptoms is allowed
  • Other active malignancy ≤ 3 years prior to registration, except for
    • Non-melanotic skin cancer
    • Carcinoma-in-situ of the cervix
    • Any cancer that, in the judgment of the investigator, has been treated with curative intent and will not interfere with the study treatment plan and response assessment
      • If there is a history of prior malignancy, they must not be receiving other specific treatment such as radiation, chemotherapy, or immunotherapy for their cancer
  • Unable or unwilling to take any prophylaxis
    • Patients with history of or new/active deep vein thrombosis/embolism/thrombophilia are allowed to participate if they are on appropriate therapeutic anticoagulation during the treatment on the trial
    • These patients would not need the aspirin with the lenalidomide unless clinically indicated
    • Patients must be able and willing to receive anticoagulation prophylactically versus therapeutically as clinically indicated
  • No history of radiation therapy to ≥ 25% of the bone marrow for other diseases
  • Receiving erythroid stimulating agents (epoetin alfa [EPO]: Procrit, Aranesp)
  • Has active or prior central nervous system (CNS) lymphoma or cerebrospinal fluid involvement with malignant lymphoma cells
    • These patients are usually treated with CNS directed therapy
    • Screening for cerebrospinal fluid CNS involvement is NOT required but can be performed per treating medical doctor  discretion
  • Active hepatitis B as defined by seropositivity for hepatitis B surface antigen (HBsAg)
    • Subjects with positive hepatitis B core antibody titers and normal liver transaminases are allowed provided that antiviral prophylaxis is administered per institutional guidelines
    • Subjects with hepatitis C antibody will be eligible provided that they do not have elevated liver transaminases or other evidence of active hepatitis

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Grzegorz Nowakowski, M.D.

Closed for enrollment

Contact information:

Cancer Center Clinical Trials Referral Office

(855) 776-0015

Jacksonville, Fla.

Mayo Clinic principal investigator

Han Tun, M.D.

Closed for enrollment

Contact information:

Cancer Center Clinical Trials Referral Office

(855) 776-0015

More information


Publications are currently not available

Additional contact information

Cancer-related trials contact form

Phone: 855-776-0015 (toll-free)

International patient clinical studies questions